Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | DUT | P33316 | 11/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL29997761 | 0.92 | L3MBTL1 (0.51) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL25786392 | 0.89 | DUT (0.62) | L3MBTL1DUTCRBNPKMPDE3A | |
| SCHEMBL7231374 | 0.85 | PKM (0.53) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL6425133 | 0.84 | L3MBTL1 (0.43) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL4348697 | 0.84 | L3MBTL1 (0.59) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL31592762 | 0.81 | L3MBTL1 (0.58) | L3MBTL1DUTCRBNPKMPDE3A | |
| SCHEMBL4286089 | 0.81 | PKM (0.57) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL24066366 | 0.81 | PKM (0.54) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL14861415 | 0.79 | L3MBTL1 (0.54) | L3MBTL1DUTCRBNPKM | |
| SCHEMBL6864606 | 0.78 | DUT (0.57) | L3MBTL1DUTCRBNPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022170198-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | USP7, USP28, USP1 | L3MBTL1 355/4885DUT 1520/4885CRBN 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.